Sigurdur Olafsson - Teva Pharma CEO
| TEVA Stock | USD 13.01 0.13 1.01% |
CEO
Mr. Sigurdur Oli Olafsson serves as President and Chief Executive Officer Global Generic Medicines Group at Teva Pharmaceutical Industries Limited since 2014. His work experience includes the following roles President of Actavis Pharma Executive Vice PresidentGlobal Generics at Actavis plc Chief Executive Officer at Actavis Group Deputy Chief Executive Officer Vice President of Corporationrationrate Development and Chief Executive Officer of Actavis Inc. US Employee at Pfizers Global RD organization in the UK and in the US and Head of Drug Development at Omega Farma in Iceland since 2014.
| Age | 46 |
| Tenure | 10 years |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Teva Pharma Management Efficiency
The company has return on total asset (ROA) of 0.0454 % which means that it generated a profit of $0.0454 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0736) %, meaning that it created substantial loss on money invested by shareholders. Teva Pharma's management efficiency ratios could be used to measure how well Teva Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Juan Alaix | Zoetis Inc | 67 | |
| Mark Zekulin | Canopy Growth Corp | N/A | |
| Richard Nanula | Lucy Scientific Discovery | 63 | |
| Brendan Kennedy | Tilray Inc | 44 | |
| Christophe Weber | Takeda Pharmaceutical Co | 58 | |
| Michael JD | Cronos Group | 37 | |
| Miguel Martin | Aurora Cannabis | 51 | |
| James Hall | Lifecore Biomedical | 61 | |
| David Klein | Canopy Growth Corp | 60 | |
| Kristin Peck | Zoetis Inc | 53 | |
| Terry Booth | Aurora Cannabis | 54 | |
| Paul Thomson | Aurora Cannabis | N/A | |
| Jeffrey Simmons | Elanco Animal Health | 57 | |
| Irwin Simon | Tilray Inc | 66 | |
| Scott Smith | Viatris | 62 | |
| Neil Swift | Takeda Pharmaceutical Co | N/A | |
Management Performance
| Return On Equity | -0.0736 | ||||
| Return On Asset | 0.0454 |
Teva Pharma Industries Leadership Team
Elected by the shareholders, the Teva Pharma's board of directors comprises two types of representatives: Teva Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharma's management team and ensure that shareholders' interests are well served. Teva Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Moshe Many, Independent Director | ||
| Richard Daniell, Executive Vice President - European Commercial | ||
| Mark Sabag, Executive Vice President, Chief Human Resources Officer and Global Communications and Brand | ||
| Ronit SatchiFainaro, Independent Director | ||
| Richard Lerner, Independent Director | ||
| Galia Maor, Independent Director | ||
| Janet Vergis, Independent Director | ||
| Carlo Notaristefani, CEO of Global Operations and President of Global Operations | ||
| Richard Francis, CEO President | ||
| JeanMichel Halfon, Statutory - independent director | ||
| Eli Shani, Executive Vice President - Global Marketing and Portfolio | ||
| Dipankar Bhattacharjee, Senior Vice President CFO Americas and Head of Finance Operations | ||
| Abbas Hussain, Independent Director | ||
| Yitzhak Peterburg, Director | ||
| Hafrun Fridriksdottir, Executive Vice President and Presidentident of Global Generics R&D | ||
| Ran Meir, Head Relations | ||
| Perry Nisen, Independent Director | ||
| Isaac Abravanel, Group Executive Vice President Teva Corporate in Israel and Global Community Alliances, Director | ||
| David Stark, Executive Vice President, Chief Legal Officer | ||
| Tal Zaks, Independent Director | ||
| Amir Elstein, Vice Chairman of the Board | ||
| Dan Suesskind, Director | ||
| Arie Belldegrun, Independent Director | ||
| Richard Egosi, Chief Legal Officer and Group Executive VP | ||
| Andrew Weil, Chief Accounting Officer | ||
| Jean Halfon, Statutory - independent director | ||
| Sven Dethlefs, Executive Vice President - Global Marketing & Portfolio and International Markets Commercial | ||
| Robert Koremans, President CEO-Global Specialty Medicines | ||
| Dov Bergwerk, Acting Secretary | ||
| Gerald Lieberman, Independent Director | ||
| Roberto Mignone, Independent Director | ||
| Rosemary Crane, Independent Director | ||
| Nechemia Peres, Independent Director | ||
| Roger Abravanel, Independent Director | ||
| Eyal Desheh, CFO and Group Executive VP | ||
| Gianfranco Nazzi, Executive Vice President - International Markets Commercial | ||
| Kare Schultz, CEO Pres | ||
| Iris BeckCodner, Group Executive Vice President - Corporate Marketing Excellence and Communication | ||
| Amir Weiss, Senior Vice President Chief Accounting Officer | ||
| Brendan OGrady, Executive Vice President - North America Commercial | ||
| Michael Hayden, President - Global Research and Development, Chief Scientific Officer | ||
| Gabrielle Sulzberger, Statutory Independent Director | ||
| Galia Inbar, Executive Vice President - Global Communications, Brand and ESG, Chief Human Resource Officer | ||
| Eric Drape, Executive Vice President - Global Operations | ||
| Vikki Conway, Acting Resources | ||
| Erez Vigodman, CEO and President Director and Member of Fin. and Invesment Committee | ||
| Eliyahu Kalif, Chief Financial Officer, Executive Vice President | ||
| Kathleen Veit, Global President | ||
| Joseph Nitzani, Independent Director | ||
| Timothy Wright, Head - Business Development, Strategy and Innovation | ||
| Sigurdur Olafsson, CEO of Global Generic Medicines Group and President of Global Generic Medicines Group | ||
| Murray Goldberg, Independent Director | ||
| Dan Propper, Independent Director | ||
| Ory Slonim, Independent Director | ||
| Michael McClellan, CFO, Executive Vice President | ||
| Kevin Mannix, Head of Global Investor Relations and VP | ||
| Kaare Schultz, President, Chief Executive Officer, Director | ||
| Sol Barer, Independent Chairman of the Board |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0736 | ||||
| Return On Asset | 0.0454 | ||||
| Profit Margin | (0.04) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 32.25 B | ||||
| Shares Outstanding | 1.13 B | ||||
| Shares Owned By Institutions | 52.65 % | ||||
| Number Of Shares Shorted | 11.56 M | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 1.99 X |
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.